The primary therapeutic application of Lecicarbon is commonly used to help with supportive relief and assists with the noticeable physiological strain associated with the lower digestive tract. The product is commonly used to help manage symptoms of constipation and is applied in clinical settings when supportive symptom management is needed. The product is commonly used across therapeutic domains where short-term symptomatic assistance is appropriate.

Managing Constipation Symptoms

The medication is used for managing symptomatic relief across various forms of constipation, including those linked to low-fiber diets or lack of physical activity, and applied in clinical settings that involve acute or unstable symptom patterns. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

Lecicarbon is used for managing specific symptoms related to symptoms that create noticeable physiological strain during elimination, such as excessive straining and the feeling of a blockage or retained stool. It supports general well-being during symptomatic phases.

Quick Fact: Supports Functional Relief
Contributes to easing symptoms related to physiological strain, which become more disruptive during flare-ups.

Lecicarbon suppositories have clear regulatory constraints regarding who is eligible to use the medicine, based on patient condition, age, and known allergies.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated for patients who fall into the following groups, as stated in the regulatory labeling:

• Individuals with a known hypersensitivity to the active substances or any of the excipients.
• Patients with an allergy to peanut or soya (due to excipient composition).
• Patients diagnosed with ileus (intestinal obstruction).
• Patients with any disease of the anal or rectal region that could lead to excessive carbon dioxide absorption, which is noted as a specific concern in children and infants.

---

Eligibility and Restrictions

Population Group	Eligibility Status
Age Groups	The correct strength must be used: Lecicarbon A for adults/adolescents, Lecicarbon C for children. Adult formulation (A) is not recommended for children.
Toxic Megacolon	Use is restricted and requires explicit permission from the treating physician.
Pregnancy	May be used after a careful risk-to-benefit evaluation by a physician.
Breastfeeding	May be used, as the carbon dioxide is not excreted in human breast milk.

The official eligibility profile is strictly defined by these safety exclusions and the mandatory matching of the product strength to the patient's age group.

Interactions with other medicines and products

The official interaction profile for the Lecicarbon suppository is distinguished by the explicit finding in regulatory documents that no interactions are known with other medicinal products. This status is formally attributed to the drug’s specific pharmacological properties.

Interaction Scope

Category	Official Regulatory Finding
Medicinal product categories with documented interactions	None documented.
Mechanistic basis of interactions	Interactions are considered not likely by regulators due to the drug’s highly localized, non-systemic action.
Timing-based interaction rules	None required or specified.
Food, Alcohol, and Supplement Interactions	No special precautions regarding co-administration with food or drink are documented in the official labeling.

Interaction Classifications

Classification	Official Regulatory Finding
Interaction severity classification	Not applicable, as no interactions are known.
Interaction-related restrictions	No formal restrictions on co-administration with any specific medicinal product are documented in the official regulatory text.

Official Interaction Statements

The regulatory documentation clearly establishes the product’s interaction structure:

• The official label explicitly states that no interactions with other medicinal products are known.
• There are no mandatory separation rules for administration time listed in the official labeling.

Connection to the overall interaction profile: Regulatory authorities define the product’s interaction structure by formally declaring the absence of known interactions. This is based on the localized action of the drug, which prevents systemic exposure from reaching levels necessary to influence the metabolism, clearance, or plasma concentration of co-administered substances.

Chemical Initiation of Physiological Gas Release

This mechanism starts with the chemical synergy of the two precursor salts, Potassium Hydrogen Tartrate and Sodium Bicarbonate, which react upon contact with rectal moisture to liberate Carbon Dioxide ( CO2) gas. The two salts must combine to produce the active mediator, defining a mechanism reliant on localized chemical synthesis rather than systemic absorption and distribution.

---

Dual Physical and Physiological Motility Stimulus

The resultant CO2 acts on two critical biological targets: it causes physical distension of the rectal wall to activate mechanoreceptors and, simultaneously, acts as a potent physiological stimulant to enhance the peristalsis of the local smooth muscle fibers . This dual action initiates the entire defaecation reflex pathway, driving the local muscular coordination required for the motor response.

---

Peripheral Mechanism and Physiological Containment

The entire action is contained within the rectosigmoid segment, ensuring the mechanism remains exclusively peripheral. Because the active chemical mediator is generated locally and the precursor salts are designed for minimal systemic absorption, the action bypasses the need for the central nervous system or distant organ systems. This targeted, non-absorbable mechanism rapidly induces the coordinated physiological events required for a motor sequence, leading to a targeted effect that avoids pharmacological interaction with non-target organ systems throughout the body.

Administration Guidelines for Lecicarbon Suppositories

The following instructions detail the procedural steps for the use of Lecicarbon, a rectal suppository.

---

Administration Scope and Dosing

Feature	Guideline
Route of Administration	Rectal (suppository)
Standard Dosing	Insert one suppository into the rectum when needed
Frequency/Timing	An individual dose may be repeated after 30 to 60 minutes if necessary
Onset of Action	Defecation is expected 15 to 30 minutes after application

---

Age-Specific Use and Preparation

Two different strengths are available for use based on age:

• Lecicarbon A Suppository (Adult strength): Intended for adults and children above 12 years of age.
• Lecicarbon C Suppository (Child strength): Intended for children.

Preparation Steps: Before use, the suppository must be removed from its packaging by separating it from the strip and pulling the plastic tabs apart. Insertion is made easier if the suppository is first dipped into water; do not use oil or petroleum jelly as a lubricant.

Lecicarbon is an as-needed medication. For pediatric use, it may be necessary to press the child's buttocks together after insertion to help retain the suppository.

Lecicarbon: Recent Clinical Evidence

Evidence for Use in Chronic Constipation Relief

Research examined the product for use in conditions characterized by functional limitations, specifically in adult outpatients experiencing chronic constipation. The studies are primarily designed as short-term, placebo-controlled trials conducted over a defined, limited time period. These trials monitored outcomes related to bowel evacuation time, the frequency of bowel movements, and changes in patient-reported outcomes describing experiences of symptom change.

Findings describe patterns observed in the studies where the data show patterns related to measurements that were observed between the product group and the placebo group. For example, some studies reported a higher percentage of measured bowel evacuations occurring within a short timeframe (such as 30 minutes). However, certainty remains low regarding long-term use, and follow-up durations were limited in many core efficacy trials.

---

Evidence for Symptoms of Difficult Defecation (Dyschezia)

Research was studied for use in conditions involving periods of heightened symptoms such as difficult defecation (dyschezia). Studies focused on adult populations and monitored the change in the intensity of outcomes related to physical discomfort over short intervals, such as three weeks.

The research highlights changes measured during the study period, with some data show patterns related to measured discomfort scores that were observed between the product group and the placebo group. What remains uncertain are the potential long-term functional changes that may be associated with difficult defecation, as the primary focus of the research was on short-term outcomes.

---

Key Limitations and Remaining Research Gaps

Comparative evidence is lacking because the core randomized controlled trials (RCTs) primarily compare the product to placebo rather than to other active ingredients. This means the research provides context but not individual predictions. Sample sizes were modest in some of the pivotal efficacy trials, and data for certain groups, such as pregnant patients or those with certain systemic imbalances, remain insufficient. Evidence for pre-procedure use relies heavily on official drug monographs and documentation of established clinical use rather than contemporary comparative trials.

Common questions about Lecicarbon (FAQ)

---

Q: What is the main difference between Lecicarbon A and Lecicarbon C?

According to official product information, the main difference between Lecicarbon A (Adult) and Lecicarbon C (Children) is the strength of the active ingredients. The children's strength (C) contains approximately half the amount of the active salts compared to the adult strength (A). This is consistent with the regulatory requirement to match the product strength to the age group.

Q: Are there any age limits for using the adult Lecicarbon A suppository?

Regulatory documents clearly state that the adult formulation, Lecicarbon A, is not suitable for use in children under 12 years of age. Official product information indicates this restriction is required to match the strength to the intended age group.

Q: Is it possible for the suppository to dissolve too quickly?

The official administration guidelines recommend dipping the suppository into water before insertion to make the process easier. However, the same guidance explicitly warns against using oil or petroleum jelly as a lubricant. This guidance is provided to ensure the product maintains stability and works as intended after insertion.

Q: Does the CO2 gas absorb into the body or stay only in the rectum?

Lecicarbon is designed for highly localized action, meaning it primarily works only within the rectum. Official pharmacokinetic information indicates that systemic toxic effects (effects on the whole body) are not expected. Any small amount of precursor ingredients that is not converted into CO2 may be absorbed and later excreted in the urine.

Q: Why does the leaflet mention allergic reactions to peanut or soya?

The reason for this warning is that the product contains the excipient, or inactive ingredient, known as soya lecithin. Because this ingredient is derived from soya, regulatory documents require a contraindication (must not use) for individuals with known allergies to either peanut or soya.

Q: Can I use Lecicarbon if I have a history of hemorrhoids or rectal fissures?

According to the official contraindications, this medicine must not be used if a patient has any disease of the anal or rectal region. Official documentation indicates that this restriction is in place due to a documented risk that these conditions could lead to excessive absorption of carbon dioxide.

Q: Does physical activity affect how well Lecicarbon works?

Official patient information, such as that provided by governmental drug agencies, advises avoiding vigorous exercise after inserting the suppository. This recommendation is made to help ensure the medicine remains in the correct position until the reflex action occurs.

Q: Is Lecicarbon a regular laxative or something different?

Lecicarbon is officially classified as a specific type of laxative known as a Carbon Dioxide producing drug ( CO2-Laxans). This classification distinguishes it from other types of laxatives because it operates by stimulating a natural defecation reflex through the physical release of CO2 gas.

Q: Why do doctors recommend this for procedures/surgeries?

Regulatory documents confirm that the medicine is officially indicated for the purpose of emptying the colon. Specifically, it is used before diagnostic or therapeutic procedures in the rectum where prompt and complete bowel clearance is necessary.

Q: Does using Lecicarbon help train my body for regular bowel movements?

Regulatory text describes Lecicarbon as a product that is not habit-forming and is safe to use for long periods. This means the body is not likely to become dependent on the drug, which is consistent with supporting the body’s natural defecation reflex.

Q: Can Lecicarbon cause stomach cramps or gas pain?

Official product information states that the mechanism of action is designed to activate intestinal movement and trigger the evacuation process without causing irritation, cramps or other side effects. This statement indicates that the mechanism is expected to activate movement without causing irritation or cramps.

Q: Can this medicine cause a feeling of not completely emptying the bowels?

A feeling of incomplete evacuation is a known possibility, as official patient information lists a sensation of inadequate defecation as a reported adverse reaction. This describes the experience of feeling that bowel evacuation was incomplete after using the product.

Q: Are there any long-term side effects from using this medicine?

Official information describes the product as being safe to use for long periods and as not habit-forming. Due to its highly localized action, systemic toxic effects (effects on the whole body) are not expected from its use.

Q: Can Lecicarbon cause diarrhea or loose stool?

Diarrhea or loose stool is listed as a possible adverse reaction in official patient information.

How to Store and Dispose of Lecicarbon

Official regulatory guidelines strictly define the conditions required to store and dispose of Lecicarbon suppositories.

---

Storage Requirements

Lecicarbon must not be stored above 25, C to maintain its stability and effectiveness. The product should not be used after the expiry date (EXP) printed on the packaging. For safety, the medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Lecicarbon must not be discarded in wastewater or with household waste. Users are officially required to ask a pharmacist how to properly throw away any unwanted medicines. This ensures adherence to local pharmaceutical waste regulations.